Behjatolah Monzavi‐Karbassi

Federal Grant PI High Impact

Associate Professor

University of Arkansas for Medical Sciences

faculty

24 h-index 79 pubs 1,590 cited

Research Areas

Cancer Immunotherapy and Biomarkers Immune Response and Inflammation Breast Cancer Treatment Studies Diet and metabolism studies Monoclonal and Polyclonal Antibodies Research Immune Cell Function and Interaction Cancer-related molecular mechanisms research Vaccine Coverage and Hesitancy

Links

ORCID Research Group

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Behjatolah Monzavi‐Karbassi's research focuses on understanding and targeting the immune response in cancer, particularly breast cancer. His work investigates the role of specific molecules and cellular interactions within the tumor microenvironment. A significant area of his research involves the development and assessment of novel vaccine strategies, such as the P10s-PADRE vaccine, in combination with chemotherapy, to elicit both humoral and cellular immune responses in patients. This includes characterizing peripheral immune correlates that predict tumor response.

Dr. Monzavi‐Karbassi also studies the therapeutic potential of targeting specific proteins, such as scavenger receptor A (SR-A), in breast cancer. His investigations extend to the influence of dietary components, like soy protein concentrates and isoflavones, on inflammatory markers and serum levels in preclinical models. Collaborations with researchers at the University of Arkansas for Medical Sciences, including Fariba Jousheghany and Bernice Nounamo, have contributed to his publication record in these areas.

His work has been supported by federal funding, including a grant from the NIH/National Cancer Institute for research on SR-A as a therapeutic target in breast cancer. Dr. Monzavi‐Karbassi leads a research group and has an h-index of 24 with over 79 publications, accumulating more than 1,590 citations.

Metrics

h-index: 24
Publications: 79
Citations: 1,590

Selected Publications

Abstract PO5-02-05: Assessing Vaccine-Mediated Cellular Immune Responses in Patients Receiving Combined Vaccine and Chemotherapy Treatment (2024) DOI
Abstract 3860: Characterizing peripheral immune correlates of tumor response in breast cancer patients immunized with the P10s-PADRE vaccine (2024) DOI
Abstract 186: Tumor exosome-macrophage interactions: The role of tumor-associated glycans and scavenger receptor class A (2024) DOI
The Tumor Microenvironment and Immune Response in Breast Cancer (2024) DOI
Abstract 700: Induction of cancer-specific T-cell responses in patients immunized with P10s-PADRE vaccine (2023) DOI
Feeding Soy Protein Concentrates with Low and High Isoflavones Alters 9 and 18 Weeks Serum Isoflavones and Inflammatory Protein Levels in Lean and Obese Zucker Rats (2023) DOI
VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen (2023) DOI
Feeding Obese Zucker Rats With Soy Protein Concentrate With High Isoflavones Compared to Low Isoflavones Leads to a Significant Reduction of Serum Tumor Necrosis Factor-α (2022) DOI
Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients (2022) DOI
P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses (2021) DOI